Gene delivery into resting immune cells

Back to search results
Genetically modified immune cells have extraordinary potential to be utilised in various immunotherapies (eg. curing HIV, untreatable malignancies and recalcitrant chronic infections). Lentiviral delivery platforms hold great promise for genetic modification, yet current platforms fail as delivery vectors due to dominant host-restrictions in resting immune cells, which have the greatest capacity for engraftment, differentiation and effector capacity. In researching known lentiviral restrictions and utilising viral evolution platforms to circumvent unknown restriction pathways, this project will be instrumental in developing new generation of lentiviral delivery platforms to resting immune cells that will be eventually used to transform the care of many recalcitrant diseases.

This project requires an individual that has great attention to detail and in meticulous in their approach to experiments at the bench. The majority of this project will be developing highly novel and unique genetic delivery platforms with high therapeutic and commercial potential. A candidate with future ambition to move into industry or academia would benefit from this PhD program and having supervisors and mentors that that span academia and industry. Previous students who have research in this field and under this team have indeed excelled at both. Finally, students that are also willing to learn new and diverse techniques and liase with a diverse range of future potential collaborators would also find this project very rewarding.

Obviously a candidate with an interest and/or training in molecular biology, virology and immunology would fit well with this project. 

Supervisory team
Stuart
Turville

Medicine
The Kirby Institute
Robert
Nordon

Engineering
Biomedical Engineering
Geoff
Symonds

CSL/Cal-Immune
Other
sturville@kirby.unsw.edu.au